Brexanolone Injection (Zulresso)

Covered only for FDA‑approved postpartum depression in adults: brexanolone (Zulresso) is covered as a single 60‑hour continuous IV infusion for moderate‑to‑severe PPD in patients ≥18 years who are ≤6 months postpartum and not pregnant; excluded are pregnant patients, those >6 months postpartum, pediatric patients, mild PPD, off‑label uses, and repeat courses. Coverage requires prescription by or consultation with a psychiatrist or obstetrician‑gynecologist and documentation of diagnosis/severity, postpartum timing, pregnancy status, age, prescriber/consultation, infusion start/stop and dosing records per the specified titration schedule, and REMS/safety program compliance.

"Zulresso is indicated for the treatment of postpartum depression (PPD) in adults."

Sign up to see full coverage criteria, indications, and limitations.